Bill's Feed
Nov 9, 2015

Lilly diabetes drug cuts heart failure death, hospitalization: study

ORLANDO (Reuters) – Eli Lilly’s new diabetes drug Jardiance significantly cut the risk of heart-related death and hospitalization for heart failure in patients with type 2 diabetes who are at high risk for serious heart problems, according to data from a large study presented on Monday.

The 3-year trial of more than 7,000 patients caused a sensation in September, when Lilly and Jardiance partner Boehringer Ingelheim released preliminary data showing the drug cut deaths by 32 percent.

Nov 8, 2015

Cytokinetics, Amgen drug shows promise in heart failure study

ORLANDO, Nov 8 (Reuters) – An experimental heart failure
drug being developed by Cytokinetics Inc and Amgen Inc
demonstrated several beneficial cardiac function
effects in a midstage clinical trial, according to data
presented on Sunday.

The trial of 448 patients with chronic heart failure already
receiving optimal care tested a twice-a-day oral version of the
drug, omecamtiv mecarbil, against a placebo over 20 weeks. After
two weeks of treatment, a group of patients had the drug dose
doubled to 50 milligrams from 25 mg.

Nov 8, 2015

Novo Nordisk diabetes drug fails to help heart failure -study

ORLANDO, Nov 8 (Reuters) – The Novo Nordisk
diabetes drug Victoza failed to improve clinical stability or
delay death in patients suffering from advanced heart failure,
researchers reported at a medical meeting on Sunday.

The injectable drug, known chemically as liraglutide, was
tested in 300 patients with and without type 2 diabetes who had
advanced heart failure and a recent hospitalization. Researchers
had hoped that the medicine’s effect on blood sugar could
mitigate some of the metabolic effects of heart failure.

Nov 6, 2015

Insight – Allergan CEO Saunders warms up to drug discovery

NEW YORK (Reuters) – Brenton Saunders, the whiz-kid pharmaceutical executive with a reputation for being wary of the costs of early-stage drug development, says he’s open to new ideas from outside and is now warming up to investing in drug discovery if it makes sense for his company.

That could ease concern that if Allergan Inc’s “friendly” talks with Pfizer Inc end in a merger, the combined company may not remain one of the world’s largest inventors of new medicines.

Nov 6, 2015

Allergan CEO Saunders warms up to drug discovery

NEW YORK, Nov 6 (Reuters) – Brenton Saunders, the whiz-kid
pharmaceutical executive with a reputation for being wary of the
costs of early-stage drug development, says he’s open to new
ideas from outside and is now warming up to investing in drug
discovery if it makes sense for his company.

That could ease concern that if Allergan Inc’s
“friendly” talks with Pfizer Inc end in a merger, the
combined company may not remain one of the world’s largest
inventors of new medicines.

Nov 6, 2015

Pfizer-Allergan deal would set up US company for a split

Nov 6 (Reuters) – A Pfizer Inc merger with
Ireland-based Allergan, in addition to providing tax
benefits, would bolster the U.S. drugmaker’s growth prospects
should it decide to sell or spin off its portfolio of products
that have gone off patent.

Many Wall Street analysts believe Pfizer will decide to
split late next year, after compiling three years of financial
data treating its “established products” division, which sells
generic medicines, and its “innovative” patent-protected
medicines unit, as if they were separate companies.

Oct 30, 2015

Pfizer, Allergan drug merger talks raise tax hackles in U.S.

By Bill Berkrot and Ransdell Pierson

(Reuters) – Pfizer Inc, the No. 1 U.S. drugmaker, and Botox maker Allergan Plc said they were in friendly talks to create a pharmaceutical colossus but the prospect that the company would seek to avoid U.S. taxes sounded political alarm bells.

Both New York-based Pfizer and Dublin-based Allergan said no agreement has been reached and declined to discuss any terms of the deal, which would potentially set up Pfizer to take advantage of Ireland’s lower tax rates.

Oct 29, 2015

Pfizer, Allergan in talks to forge world’s biggest drugmaker

By Bill Berkrot and Ransdell Pierson

(Reuters) – Botox maker Allergan Plc (AGN.N: Quote, Profile, Research) and Pfizer Inc (PFE.N: Quote, Profile, Research) on Thursday said they were in early, friendly talks to create the world’s largest drugmaker, a deal that would potentially set up Pfizer to take advantage of Ireland’s lower tax rates.

Both New York-based Pfizer and Dublin-based Allergan said no agreement has been reached and declined to discuss any terms.

Oct 29, 2015

Pfizer, Allergan say in talks on merger

Oct 29 (Reuters) – Botox maker Allergan Plc and
Pfizer Inc on Thursday confirmed they were in
preliminary, friendly talks on a potential merger, a deal that
would create the world’s largest drugmaker.

Both Pfizer and Ireland-based Allergan said no agreement has
been reached and declined to discuss any terms that might lead
to such a tie-up.

Oct 29, 2015

Allergan says in talks on merger with Pfizer

By Bill Berkrot and Ransdell Pierson

(Reuters) – Botox maker Allergan Plc on Thursday said it was in preliminary, friendly talks with Pfizer Inc on a potential merger, a deal that would create the world’s largest drugmaker.

Ireland-based Allergan said there was no certainty the talks would lead to a deal, and did not discuss the terms that might lead to a tie-up with Pfizer.

    • About Bill

      "Based in New York, I primarily cover the pharmaceutical and biotechnology sectors as well as other publicly traded companies involved in health care. Previously covered a wide range of sports for Reuters."
    • Follow Bill